Immunome, Inc. · NASDAQ:IMNM
Immunome — Investor Presentation (October 2020)
33 slides from Immunome's investor presentation, Oct 26, 2020
Slide 1: Developing Antibody-Based Therapeutics by Unlocking the Human Memory B Cell Response
Developing Antibody - Based Therapeutics by Unlocking the Human Memory B Cell Response Immunome, Inc. 665 Stockton Drive, Suite 300 Exton, PA 19341 610.321.3700 www.immunome.com October 26, 2020
Slide 2: Forward Looking Statements
This presentation contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends forward - looking terminology such as “believes,” “anticipates,” “plans,” “may,” “intends,” “will,” “should,” “exp ects,” and similar expressions
Slide 3: Immunome Overview
Immunome Overview Harnessing the power of the most - educated components of the human immune system • Immunome leverages its proprietary Discovery Engine, which enables unbiased interrogation of human memory B cells, to simultaneously identify potential first - in - class antibody therapeutics and n
Slide 4: Immunome Approach
Immunome, Inc. | Page 4 Immunome Approach Our approach harnesses the power of human memory B cells to discover first - in - class therapeutic monoclonal antibody candidates directed at potentially novel targets Partnerships • Contract from U.S. Department of Defense to fund COVID - 19 program, up to
Slide 5: The Power of Memory B Cells
The Power of Memory B Cells Memory B cells are critical players in human immune response • Memory B cells are a subset of B cells that remember specific antigens and allow for a rapid antibody response upon re - challenge 1 • Memory B cells produce the high - affinity antibodies needed to fight dise
Slide 6: Immunome Discovery Engine
Immunome Discovery Engine Unbiased interrogation of memory B cells reveals potentially novel targets • Primary human memory B cells immortalized as stable hybridomas. Thousands of hybridomas per patient • High - throughput screening (20,000 antibodies / array). Deep interrogation of patient response
Slide 7: Immunome Pipeline & Anticipated Milestones
Immunome, Inc. | Page 7 Immunome Pipeline & Anticipated Milestones Oncology Target Product Candidate Description Discovery Next Milestone IMM - ONC - 01 IL - 38 I/O, Novel Checkpoint Anticipate IND filing 2H 2021 Anti - infectives Target Product Candidate Description Discovery Next Milestone IMM - B
Slide 8: Oncology
Vv immunome Oncology
Slide 9: Oncology Landscape Today
Oncology Landscape Today Immunome, Inc. | Page 9 • Despite significant advances, the five - year survival rate for patients with advanced malignancies of the lung, liver, stomach, pancreas and other organs is less than 10% • Discovery of new targets and novel therapeutics for cancer treatment is vit
Slide 10: Challenges with Oncology Therapies
Challenges with Oncology Therapies • T cell targeted immuno - oncology approaches have redefined the way we treat cancer • Large number of patients, however, cannot be treated using T cell - targeted approaches • Tumors subvert immunity by multiple mechanisms, often simultaneously 1 • T cell compart
Slide 11: Immunome's Discovery & Output
Immunome’s Discovery & Output Novel “target clusters“ focus on a subset of biological functions 1. Including some commercially - validated targets such as ERBB2 2. Adv Clin Chem. 2016;74:103 - 41.DOI: 10.1016/bs.acc.2015.12.005 3. Mol Cancer. 2019 Oct 23;18(1):146. doi: 10.1186/s12943 - 019 - 1074 -
Slide 12: IMM-ONC-01 (IL-38)
IMM - ONC - 01 (IL - 38) Immunome, Inc. | Page 12 Immunome Discovery Engine identified the potential utility of targeting IL - 38 • Immunome’s Discovery Engine identified the potential utility of targeting IL - 38 through interrogation of the memory B cells from a patient with head and neck cancer •
Slide 13: IL-38 Expression in Patient Tumors
IL - 38 Expression in Patient Tumors Immunome, Inc. | Page 13 Inverse relationship between high IL - 38 expression and immune cell populations in tumors 1. Immunome analysis of the Cancer Genome Atlas (TCGA) data from Firehouse Legacy dataset 2. Takada et al PLOS ONE 2017 doi.org/10.1371/journal.pon
Slide 14: IMM-ONC-01 Hit antibodies are specific for IL-38
IMM - ONC - 01 Immunome, Inc. | Page 14 Hit antibodies are specific for IL - 38 • IL - 38 is a lesser - known member of the IL - 1 family of cytokines • It regulates adaptive and innate immune responses by binding to receptors found on immune cell subsets (e.g., macrophages, gd T cells, dendritic ce
Slide 15: IL-38 & Inflammation
IL - 38 & Inflammation Immunome, Inc. | Page 15 IL - 38 modulates global inflammatory response associated with lipopolysaccharide, LPS, stimulation Treating with anti IL - 38 antibody antagonizes the effect of IL - 38 LPS + IL38 Principal Component 1 Principal Component 2 LPS only Unstimulated Princ
Slide 16: IL-38 & Innate Immune Response
IL - 38 & Innate Immune Response Immunome, Inc. | Page 16 Vehicle Control CD1-M3 0 2000 4000 6000 g d T c e l l s / g m o f t u m o r Cells per gram of B16.F10 tumor: gd T cells Immunome antibody reverses IL - 38 suppression of immune cells in pre - clinical models Dendritic Cell Precursors Macropha
Slide 17: Immunome Antibody Induces Tumor Response
Immunome Antibody Induces Tumor Response Immunome, Inc. | Page 17 In vivo tumor response in B16F10 tumor model • IL - 38 is expressed by some animal models, including the syngeneic B16F10 murine melanoma model • Preliminary data in B16F10 model suggest treating with CD1 - M3, our antibody, appears t
Slide 18: IMM-ONC-01 Program Summary
IMM - ONC - 01 Program Summary Immunome, Inc. | Page 18 Modulating innate immunity • IL - 38 regulates adaptive and innate immune responses by binding to receptors found on immune cell subsets • Modulation of IL - 38 levels in mouse models correlates with immune responsiveness and tumor growth • Imm
Slide 19: Infectious Diseases
Vv immunome Infectious Diseases
Slide 20: Infectious Disease Application (COVID-19)
Infectious Disease Application (COVID - 19) Immunome, Inc. | Page 20 Convalescent plasma treatments: while promising, challenges remain 1. Image: J Clin Invest DOI: 10.1172/JCI138003 2. Jiang et al https://doi.org/10.1101/2020.03.20.20039495 3. Bloch et al J Clin Invest https://doi.org/10.1172/JCI13
Slide 21: COVID-19 Biosynthetic Convalescent Plasma (BCP)
COVID - 19 Biosynthetic Convalescent Plasma (BCP) Immunome, Inc. | Page 21 Single neutralizing antibody approach versus Immunome’s Biosynthetic Convalescent Plasma Neutralization Complement Fixation Phagocytosis Immunome’s BCP approach aims to leverage multiple viral clearance mechanisms to maximize
Slide 22: Biosynthetic Convalescent Plasma Concept
Biosynthetic Convalescent Plasma Concept Collaboration with U.S. DoD awarded, up to $13.3M in funding Immunome, Inc. | Page 22 Produce antibody mixture (up to 6 Abs) using recombinant manufacture Select convalescent patients with strong anti - viral titer Biosynthetic Convalescent Plasma for potenti
Slide 23: Anti-SARS-CoV-2 Antibodies from Super-Responders
Anti - SARS - CoV - 2 Antibodies from ”Super - Responders” More than 50% of the antibodies identified bind to SARS - CoV - 2 proteins other than Spike Immunome, Inc. | Page 23 • Immunome leverages both cell - and protein - based screening methods to identify antibodies from “super - responder” COVID
Slide 24: IMM-BCP-01 Program Summary
IMM - BCP - 01 Program Summary Immunome, Inc. | Page 24 • Leverages the unbiased nature of the Immunome Discovery Engine to both capture the memory B cells of convalescent COVID - 19 patients and identify antibodies against multiple viral proteins – Patients make antibodies to multiple viral protein
Slide 25: Immunome Summary
Immunome Summary Harnessing the power of the most - educated components of the human immune system Immunome, Inc. | Page 25 • Immunome leverages its proprietary Discovery Engine, which enables unbiased interrogation of human memory B cells, to simultaneously identify potential first - in - class ant
Slide 26: Appendix
Vv immunome Appendix
Slide 27: Management Team
Management Team Michael Morin, PhD Chief Science Officer Oversaw cancer, immunology and anti - bacterial drug discovery Richard F. Fitzgerald Chief Financial Officer Former CFO of Sesen Bio, PAVmed , TechPrecision and Nucleonics, Inc. Jillian DiMuzio Senior Director, HTS & Automation Pavel Nikitin,
Slide 28: Board of Directors
Michael Rapp Managing Partner, Broadband Capital Investments, LLC Richard Baron Formerly Chief Financial Officer, Zynerba Pharmaceuticals John LaMattina, PhD Formerly President, Pfizer Global Research & Development Michael Lefenfeld President and CEO, Cyanco International Co - founder of SiGNa Chemi
Slide 29: Scientific Advisory Board
Scott Dessain, MD, PhD Chair, Founder Joseph and Ray Gordon Chair of Clinical Oncology and Research at Lankenau Institute for Medical Research George Prendergast, PhD Cancer Biology Former Editor of Cancer Research President and CEO of Lankenau Institute for Medical Research William Strohl, PhD Anti
Slide 30: COVID-19 Advisory Board
Michael Diamond , MD, PhD Washington University School of Medicine The Herbert S. Gasser Professor of Medicine and Professor of Molecular Biology Pathology and Immunology Associate Director, for the Andrew M. and Jane M. Bursky Center for Human Immunology and I mmunotherapy Programs. Jeffery Henders
Slide 31: Proprietary Screening
Proprietary Screening Interrogation of patient response with depth, breadth and speed Every antibody screened against approximately 100 antigen sources To date, 1,200+ screening hits identified 20,000 antibodies per array • Proprietary high - throughput screening methodologies • Deep interrogation o
Slide 32: Target Identification & Validation
Target Identification & Validation High success rate in identifying potentially novel oncology targets Immunome, Inc . | Page 32 • Define targets by cross - referencing with > 80% of the predicted human proteome To date, 50+ potentially novel antibody / antigen pairs identified **Antibodies bound to
Slide 33: Stockton Drive, Suite Exton, PA 19341 610.321.3700 www.immunome.com
665 Stockton Drive, Suite 300 Exton, PA 19341 610.321.3700 www.immunome.com